Background: Patients with rheumatoid arthritis (RA) are at increased risk for heart failure (HF) and vascular events. Small elevations in circulating N-terminal pro-brain natriuretic peptide (NT-proBNP) are associated with increased cardiovascular event risk, and high levels signal left ventricular dysfunction. Data on the effects of a TNFα blocking agents on circulating NT-proBNP levels in active RA patients are lacking, but may be informative.
Methods: 171 consecutive RA patients (disease activity score-28 above 3.2) without congestive HF (NYHA class III or IV) were scheduled to receive adalimumab once every 2 weeks. Serum NT-proBNP concentrations were measured simultaneously on stored baseline and 16 week samples. Paired sample t-tests were used to observe differences in biomarkers before and after adalimumab administration. Pearson’s test evaluated biomarker correlations with changes in circulating log NT-proBNP levels, and multivariable linear regression analyses of correlates were performed (forward selection procedure).
Results: Circulating levels of NT-proBNP decreased significantly after 16 weeks of adalimumab administration: median NT-proBNP 83.0 pg/ml versus 69.5 pg/ml, p = 0.004. Changes in NT-proBNP were associated with changes in pulse pressure (r = 0.18, p = 0.02), systolic blood pressure (r = 0.16, p = 0.04), and ESR (r = 0.18, p = 0.02). On multivariable analysis, changes in pulse pressure and ESR remained independently associated with changes in circulating NT-proBNP.
Discussion: Our novel observations demonstrate that blocking TNFα in RA patients without evident HF decreases NT-proBNP levels by around 18%. This suggests no treatment-induced deterioration in cardiac function, and a potential CV risk benefit.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.